Celalettin Ustun

Celalettin Ustun is a Professor of Medicine at Rush University, specializing in hematology, oncology, and transplantation medicine. His research focuses on clinical transplantation, particularly allogeneic hematopoietic cell transplantation for acute myeloid leukemia (AML) and advanced systemic mastocytosis. He investigates measurable residual disease, FLT3-ITD mutations, and post-transplant maintenance therapies, including gilteritinib. His recent work has been published in Blood and Blood Advances, covering CAR T-cell therapy outcomes in large B-cell lymphoma and artificial intelligence-based assessments of avapritinib effects. He leads international collaborative studies through CIBMTR and has contributed to pivotal trials, including the SUMMIT trial for bezuclastinib in non-advanced systemic mastocytosis.